Incyte

From Wikipedia, the free encyclopedia
Incyte Corporation
TypePublic
Nasdaq: INCY
NASDAQ-100 Component
S&P 500 Component
Industrypharmaceutical company
Founded2002 (2002)
Headquarters
1801 Augustine Cut-off
Wilmington, Delaware
,
United States
Key people
Hervé Hoppenot (Chairman, President, and CEO, 2014)
RevenueIncrease $US 2.67 billion (2020)
Decrease $US (296) million (2020)[1][2]
Total assetsIncrease $US 3.56 billion (2020)
Total equityIncrease $US 2.611 billion (2020)
Number of employees
1600+[3] (2020)
Websitewww.incyte.com
Footnotes / references
[4]

Incyte Corp is an American multinational pharmaceutical company based in Wilmington, Delaware.[5] The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991[6] and Incyte Genomics, Inc. of Delaware.[7] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.[8]

Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

History[]

In 2014, Incyte named Hervé Hoppenot president and CEO, and in 2015 he was appointed chairman of the Board of Directors.[9][10] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[10]

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, , in a deal worth $795+ million.[11]

In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[12] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[13]

Pharmaceuticals[]

Incyte Corporation currently has four marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix) and Iclusig (ponatinib).[14]

In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.[15]

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[16][17] It gained EU approval in February 2017.[18] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[19][20] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.[21][22]

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[23][24]

References[]

  1. ^ https://www.nasdaq.com/market-activity/stocks/incy/financials
  2. ^ https://www.macrotrends.net/stocks/charts/INCY/incyte/net-income
  3. ^ "Incyte". Fortune 500. Fortune Media IP Limited. 18 May 2020. Company information. Retrieved 19 December 2020.
  4. ^ Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, archived from the original on January 26, 2013, retrieved May 6, 2012
  5. ^ "INCY". www.nasdaq.com. Retrieved 2021-07-26.
  6. ^ Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
  7. ^ "Certificate of Ownership and Merger". www.sec.gov. Retrieved 2021-07-26.
  8. ^ "Headquarters - Pharmaceutical Research & Development | Incyte". www.incyte.com. Retrieved 2021-07-27.
  9. ^ "Leadership | Incyte". www.incyte.com. Retrieved 2021-07-26.
  10. ^ Jump up to: a b "People". Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 41.
  11. ^ "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.
  12. ^ "MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab".
  13. ^ "MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab".
  14. ^ "incy_Current folio_10K". www.sec.gov. Retrieved 2021-07-26.
  15. ^ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. Retrieved 2015-12-29.
  16. ^ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Archived from the original on 8 March 2015. Retrieved 2 Mar 2015.
  17. ^ "Baricitinib" (PDF). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
  18. ^ "Olumiant: Authorisation details". European Medicines Agency. 16 March 2017.
  19. ^ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
  20. ^ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
  21. ^ Research, Center for Drug Evaluation and (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA.
  22. ^ "Drug Approval Package: Olumiant (baricitinib)". www.accessdata.fda.gov. Retrieved 2021-07-27.
  23. ^ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European Journal of Cancer (Oxford, England : 1990). 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
  24. ^ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.

External links[]

Retrieved from ""